Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • Artesunate mefloquineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Artesunate + MefloquineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 4
1
25%
Not Applicable
1
25%
Phase 3
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (50.0%)
Phase 41 (25.0%)
N/A1 (25.0%)

Trials by Status

unknown125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

NCT03893097
unknownphase_4

Malaria Elimination Pilot Study in Military Forces in Cambodia

NCT02653898
completednot_applicable

Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia

NCT00493363
completedphase_3

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

NCT02974348

Clinical Trials (4)

Showing 4 of 4 trials
NCT03893097Phase 3

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

Completed
NCT02653898Phase 4

Malaria Elimination Pilot Study in Military Forces in Cambodia

Unknown
NCT00493363Not Applicable

Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia

Completed
NCT02974348Phase 3

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Completed

All 4 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
4